# Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

> **NCT04000009** · PHASE3 · TERMINATED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 235 (actual)

## Conditions studied

- Adjunctive Treatment of Major Depressive Disorder

## Interventions

- **DRUG:** Pimavanserin

## Key facts

- **NCT ID:** NCT04000009
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-06
- **Primary completion:** 2021-02-22
- **Final completion:** 2021-02-22
- **Target enrollment:** 235 (ACTUAL)
- **Why stopped:** The study was terminated for business reasons and not due to safety concerns.
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04000009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04000009, "Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04000009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*